Study Group: Albuterol Prescribers (US)
Council Members in this Study Group: 15
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Mark Vandewalker
Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks Ltd
Mark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost...
David EnglerPhysician
The Allergy ClinicDavid Engler, MD, a graduate of Baylor College of Medicine, has worked at The Allergy Clinic since 1991. He has served two terms on the Board of Regents of the American College of Allergy, Asthma & Immunology, and has represented that organization at...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
FDA Poised to Damage Asthma Pharmacotherapy Advances
December 10, 2008
FDA: Long-Acting Asthma Drugs Increase Asthma Risks | online.wsj.com
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary function, symptoms scores, and need for rescue medication. However, some long-term safety studies have demonstrated increased risk of severe asthma exacerbations when these LABAs are used as monotherapy without concomitant inhaled steroid therapy. Based on this data, the FDA is considering the withdrawal of LABAs from the US market. I anticipate the FDA will come to their senses and appreciate the significant benefit that combination LABA/ICS therapy has in the vast majority of moderate and severe asthmatics for whom they are appropriately prescribed. In my opinion, cessation of LABA therapy for asthma would return us to asthma mortality rates not seen since the 1990s.
-
They'll fix this before the end of the month
July 2, 2008
Analysis by: David Engler, Physician,Medicare fees to doctors fall Tuesday | news.yahoo.com
If this isn't fixed, it won't be long before cognitive specialties, like internal medicine and neurology, start capping their practices and not allowing new Medicare patients.
-
This may have a market after all
July 2, 2008
Analysis by: David Engler, Physician,Taro Receives Final FDA Approval For RX Cetirizine Hydrochloride Syrup ANDA | www.medicalnewstoday.com
Here comes a prescription version of generic Zyrtec syrup. At first glance, we wonder how it will compete with over the counter Zyrtec. But wait...there may be a market for this drug
-
Next-Generation Xolair (omalizumab) sounds pretty good
June 18, 2008
Analysis by: David Engler, Physician,Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
This drug seems much more effective at reducing free-IgE levels than is Xolair. Overall, Xolair has given many patients a tremendous improvement in their quality of life, but it hasn't fulfilled many of its promises. Frankly, some of Xolair's benefits are disappointing, particularly in the 40 or 50% of patients who use it without achieving great results. In particular, Xolair patients who are on Advair 500/50 can sometimes get down to Advair 250/50, but it's been difficult tapering them to lower doses of inhaled corticosteroids.
-
Will Xolair Become Obsolete in the Treatment of Allergies?
June 10, 2008
Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant potential to replace omalizumab as effective anti-IgE therapy with just one dose, even in patients with very high initial levels of total IgE. The potential market share for such a treatment is enormous since at least 25% of the population suffers from Ige-mediated diseases such as allergic rhinitis, asthma, atopic eczema, and food allergy.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Hospice Facility
- Other Freestanding Healthcare Facility
- Laboratory, Independent
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Director
- Owner
- Medical Director
- Partner